NEW YORK (GenomeWeb News) – Selventa today announced a research agreement with Janssen Research & Development in immunological diseases.
The deal includes the development of disease models to shed information about disease-relevant mechanisms and to identify new drug discovery opportunities, Selventa said. Aside from saying the deal is multi-year the company did not disclose the terms.
Selventa and an affiliate of Janssen R&D earlier collaborated on a joint publication that sought to identify genes associated with intestinal permeability post anti-TNF therapy in ulcerative colitis, David de Graaf, president and CEO of Selventa said in a statement.
"Building comprehensive disease models and investigating different molecular mechanisms may provide key data-driven foundation for appropriate selection of druggable mechanisms within a disease," he said.
Selventa, a life science data analysis firm based in Cambridge, Mass., raised $5 million in late 2011.